Sandoz May Turn To Novartis Sales Force For Omnitrope Marketing
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz' follow-on human growth hormone cleared FDA May 30, but the agancy asserts that the approval does not create a biosimilar regulatory pathway.
You may also be interested in...
Sandoz VP-Biopharma Development Ajaz Hussain: An Interview With “The Pink Sheet” DAILY
In the wake of Omnitrope’s approval in the U.S. and Europe, Sandoz is moving forward with a robust biosimilar pipeline.
Sandoz VP-Biopharma Development Ajaz Hussain: An Interview With “The Pink Sheet” DAILY
In the wake of Omnitrope’s approval in the U.S. and Europe, Sandoz is moving forward with a robust biosimilar pipeline.
Just A Product, Not A Pathway, FDA Says Of Omnitrope Approval
Sandoz' follow-on human growth hormone does not establish a precedent for follow-on proteins for biologics regulated under the Public Health Service Act.